Clinical

Articles

Addressing the gaps in health literacy may lead to improvement in health outcomes and health care disparities among patients with chronic pelvic pain.

Study assesses impact of health literacy on chronic pelvic pain

Elisabeth M. Sebesta, MD, coauthor of a recent study, reported that patients who experienced more unmet social needs were at increased risk of multiple urologic conditions, such as overactive bladder, interstitial cystitis, or urge incontinence. 

Recent study associates unmet social needs with urologic conditions

In this interview, Andrea Staack, MD, PhD, discusses the background, findings, and takeaways of the study, "Mindfulness based-stress reduction is associated with decreased levels of patients’ anxiety after urodynamics- A prospective randomized controlled trial," along with why urologists should consider implementing more strategies of this effect in their practices.

Study investigates mindfulness-based stress reduction for urodynamics

Podcasts

“We need to just approach STIs as the medical conditions they are because until we do, and until we take those stigmas away, people will truly have resistance to discussing it, hesitance to discussing it, and resistance to diagnosis and intervention,” says Ashley Winter, MD.

Destigmatizing Urology: Dr. Winter discusses STDs/STIs

In this interview, Ashley Winter, MD, discusses why urologists should play a role in the management of STDs and STIs, especially when it comes to destigmatizing them. 

Common misconceptions associated with STDs/STIs and what urologists can do to resolve them

“I think people can feel like they're all alone, or they have something that's uncommon, and it may not be,” says J. Quentin Clemens, MD, FACS, MSCI.

Destigmatizing Urology: Dr. Clemens discusses interstitial cystitis

"Certainly, the Optilume drug-coated balloon appears to be safe and effective in roughly two-thirds of patients at 3 years," said Justin Chee, MD.

Dr. Chee summarizes latest Optilume data in patients with urethral strictures 

“Optilume exhibited a significant improvement in [the primary] objective outcome at 6 months and subjective outcomes at 1-year post treatment compared to standard of care,” said Justin Chee, MBBS, FRACS.

Optilume drug-coated balloon superior to standard care for recurrent anterior urethral strictures

In the pivotal phase 3 DAPA-CKD trial, dapagliflozin reduced the relative risk of worsening of renal function, onset of end-stage kidney disease, or cardiovascular or renal death by 39%.

Dapagliflozin approved in Europe for CKD, regardless of diabetes status

The FDA’s decision not to approve roxadustat follows a vote from the agency’s Cardiovascular and Renal Drugs Advisory Committee that the drug’s benefit-risk profile does not support approval.

Benign Conditions